维利帕尼联合卡铂紫杉醇治疗BRCA突变晚期乳腺癌(BROCADE3):随机双盲安慰剂对照3期试验
BROCADE3是在36个国家147家医院开展的随机双盲安慰剂对照3期试验,纳入gBRCA1/2突变、HER2阴性晚期乳腺癌患者,比较维利帕尼或安慰剂联合卡铂-紫杉醇(双药停药后可继续单药维持)的疗效。
要点
- 维利帕尼联合卡铂-紫杉醇较安慰剂显著改善gBRCA突变晚期乳腺癌的无进展生存期。
- 双药化疗因毒性停药后可继续维利帕尼单药维持直至疾病进展。
- 3级及以上不良事件以中性粒细胞减少、贫血和血小板减少最常见。
核心结论
- 在gBRCA突变相关晚期乳腺癌中,维利帕尼加入高效铂类双药方案并在双药停用后继续单药维持,可显著且持久地改善无进展生存期。
- 数据支持在该患者人群中联合使用铂类与PARP抑制剂。
研究设计与样本
- BROCADE3为随机、双盲、安慰剂对照3期试验,在36个国家147家医院开展。
- 纳入年龄≥18岁、gBRCA1/2致病变异相关、组织学或细胞学确诊的HER2阴性晚期乳腺癌患者,ECOG体能状态0-2,既往转移性疾病化疗不超过两线。
- 按2:1随机分配至维利帕尼组或安慰剂组,随机分层因素为既往铂类使用、CNS转移史及雌激素和孕激素受体状态。
- 主要终点为研究者按RECIST 1.1评估的无进展生存期,疗效分析采用意向治疗人群(n=509)。
主要发现
- 意向治疗人群509例中,维利帕尼组337例、对照组172例。
- 3级及以上不良事件最常见为中性粒细胞减少(维利帕尼组272/336例[81%] vs 对照组143/171例[84%])、贫血(142例[42%] vs 68例[40%])和血小板减少(134例[40%] vs 48例[28%])。
- 严重不良事件维利帕尼组115例(34%)、对照组49例(29%),无研究药物相关死亡。
关键数值与推荐
- 卡铂按浓度-时间曲线下面积6 mg/mL/min静脉给药,第1天。
- 紫杉醇80 mg/m2静脉给药,第1、8、15天,21天为一周期。
- 维利帕尼120 mg口服每日两次,第-2至5天给药;双药停药后可按强化剂量300 mg每日两次持续给药,耐受时增至400 mg每日两次。
- 对照:匹配安慰剂;对照组疾病进展后可接受开放标签维利帕尼单药治疗。
临床怎么用
- 对gBRCA1/2突变、HER2阴性晚期乳腺癌,可考虑铂类双药联合PARP抑制剂维利帕尼,并在双药因毒性停用后以维利帕尼单药维持。
- 用药期间需重点监测中性粒细胞减少、贫血和血小板减少等血液学毒性。
- 该方案适用于既往转移性疾病化疗不超过两线的患者。
局限性
- 试验仍在进行中,本报告为数据截止2019年4月5日的分析结果。
- 主要终点为研究者评估的无进展生存期,总生存数据尚未报告。
- 安全性分析仅纳入至少接受一剂维利帕尼或安慰剂的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BRCA1 or BRCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors and platinum agents owing to deficiency in homologous recombination repair of DNA damage. In this trial, we compared veliparib versus placebo in combination with carboplatin and paclitaxel, and continued as monotherapy if carboplatin and paclitaxel were discontinued before progression, in patients with HER2-negative advanced breast cancer and a germline BRCA1 or BRCA2 mutation. METHODS: BROCADE3 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 147 hospitals in 36 countries. Eligible patients (aged ≥18 years) had deleterious germline BRCA1 or BRCA2 mutation-associated, histologically or cytologically confirmed advanced HER2-negative breast cancer, an Eastern Cooperative Oncology Group performance status of 0-2, and had received up to two previous lines of chemotherapy for metastatic disease. Patients were randomly assigned (2:1) by interactive response technology by means of permuted blocks within strata (block size of 3 or 6) to carboplatin (area under the concentration curve 6 mg/mL per min intravenously) on day 1 and paclitaxel (80 mg/m2 intravenously) on days 1, 8, and 15 of 21-day cycles combined with either veliparib (120 mg orally twice daily, on days -2 to 5) or matching placebo. If patients discontinued carboplatin and paclitaxel before progression, they could continue veliparib or placebo at an intensified dose (300 mg twice daily continuously, escalating to 400 mg twice daily if tolerated) until disease progression. Patients in the control group could receive open-label veliparib monotherapy after disease progression. Randomisation was stratified by previous platinum use, history of CNS metastases, and oestrogen and progesterone receptor status. The primary endpoint was investigator-assessed progression-free survival per Response Evaluation Criteria in Solid Tumors version 1.1. Efficacy analyses were done by intention to treat, which included all randomly assigned patients with a centrally confirmed BRCA mutation, and safety analyses included all patients who received at least one dose of velilparib or placebo. This study is ongoing and is registered with ClinicalTrials.gov, NCT02163694. FINDINGS: Between July 30, 2014, and Jan 17, 2018, 2202 patients were screened, of whom 513 eligible patients were enrolled and randomly assigned. In the intention-to-treat population (n=509), 337 patients were assigned to receive veliparib plus carboplatin-paclitaxel (veliparib group) and 172 were assigned to receive placebo plus carboplatin-paclitaxel (control group). Median follow-up at data cutoff (April 5, 2019) was 35·7 months (IQR 24·9-43·6) in the veliparib group and 35·5 months (23·1-45·9) in the control group. Median progression-free survival was 14·5 months (95% CI 12·5-17·7) in the veliparib group versus 12·6 months (10·6-14·4) in the control group (hazard ratio 0·71 [95% CI 0·57-0·88], p=0·0016). The most common grade 3 or worse adverse events were neutropenia (272 [81%] of 336 patients in the veliparib group vs 143 [84%] of 171 patients in the control group), anaemia (142 [42%] vs 68 [40%]), and thrombocytopenia (134 [40%] vs 48 [28%]). Serious adverse events occurred in 115 (34%) patients in the veliparib group versus 49 (29%) patients in the control group. There were no study drug-related deaths. INTERPRETATION: The addition of veliparib to a highly active platinum doublet, with continuation as monotherapy if the doublet were discontinued, resulted in significant and durable improvement in progression-free survival in patients with germline BRCA mutation-associated advanced breast cancer. These data indicate the utility of combining platinum and PARP inhibitors in this patient population. FUNDING: AbbVie.
引用
- Diéras V, Han HS, Kaufman B, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020. PMID: 32861273. doi:10.1016/S1470-2045(20)30447-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。